Day One Biopharmaceuticals (DAWN) Operating Income (2023 - 2025)
Historic Operating Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$24.3 million.
- Day One Biopharmaceuticals' Operating Income fell 18182.95% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 2167.41%. This contributed to the annual value of -$217.3 million for FY2024, which is 543.81% down from last year.
- Per Day One Biopharmaceuticals' latest filing, its Operating Income stood at -$24.3 million for Q3 2025, which was down 18182.95% from -$35.0 million recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Operating Income ranged from a high of $29.6 million in Q3 2024 and a low of -$114.8 million during Q2 2024
- Over the past 3 years, Day One Biopharmaceuticals' median Operating Income value was -$50.3 million (recorded in 2023), while the average stood at -$47.8 million.
- In the last 5 years, Day One Biopharmaceuticals' Operating Income skyrocketed by 15761.5% in 2024 and then tumbled by 18182.95% in 2025.
- Over the past 3 years, Day One Biopharmaceuticals' Operating Income (Quarter) stood at -$59.5 million in 2023, then decreased by 9.77% to -$65.3 million in 2024, then surged by 62.88% to -$24.3 million in 2025.
- Its Operating Income stands at -$24.3 million for Q3 2025, versus -$35.0 million for Q2 2025 and -$41.1 million for Q1 2025.